Showing results (61-70 of 154) with videos related to
Sort By:
Pageof 16
Noro Psikiyatri Arsivi|December 20, 2021
Neuropathic Pain Frequency in Neurology Outpatients: A Multicenter StudyCan Ebru Bekircan-Kurt, Berin Inan, Onur Bulut, et al.Neurology|July 1, 2021
Effects of High- and Low-Efficacy Therapy in Secondary Progressive Multiple SclerosisIzanne Roos, Emmanuelle Leray, Romain Casey, et al.Multiple Sclerosis (Houndmills, Basingstoke, England)|July 9, 2020
Prediction of on-treatment disability worsening in RRMS with the MAGNIMS scoreAmy Kunchok, Jeannette Lechner-Scott, Franco Granella, et al.Multiple Sclerosis Journal - Experimental, Translational and Clinical|May 27, 2024
Comparative effectiveness of dimethyl fumarate versus non-specific immunosuppressants: Real-world evidence from MSBaseTim Spelman, Sara Eichau, Raed Alroughani, et al.Journal of Neurology, Neurosurgery, and Psychiatry|March 7, 2024
Comparing ocrelizumab to interferon/glatiramer acetate in people with multiple sclerosis over age 60Yi Chao Foong, Daniel Merlo, Melissa Gresle, et al.Journal of Neurology, Neurosurgery, and Psychiatry|July 6, 2023
Risk of secondary progressive multiple sclerosis after early worsening of disabilityWinston Dzau, Sifat Sharmin, Francesco Patti, et al.Multiple Sclerosis (Houndmills, Basingstoke, England)|November 2, 2018
International consensus on quality standards for brain health-focused care in multiple sclerosisJeremy Hobart, Amy Bowen, George Pepper, et al.Multiple Sclerosis and Related Disorders|December 20, 2025
Real-world effectiveness of ocrelizumab in relapsing multiple sclerosis: An MSBase registry sub-studyHelmut Butzkueven, Pamela Farr, Serkan Ozakbas, et al.Multiple Sclerosis (Houndmills, Basingstoke, England)|November 26, 2016
Quantifying risk of early relapse in patients with first demyelinating events: Prediction in clinical practiceTim Spelman, Claire Meyniel, Juan Ignacio Rojas, et al.Neurology|August 11, 2017
Anti-inflammatory disease-modifying treatment and short-term disability progression in SPMSJohannes Lorscheider, Vilija G Jokubaitis, Tim Spelman, et al.Pageof 16